Calliditas Therapeutics Q1 EPS $(0.88) Down From $(0.33) YoY, Sales $28.43M Up From $18.32M YoY
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics (NASDAQ:CALT) reported a Q1 EPS of $(0.88), a significant decrease from $(0.33) YoY, but saw a 55.21% increase in sales to $28.43M.
May 23, 2024 | 6:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Calliditas Therapeutics reported a significant decrease in Q1 EPS to $(0.88) from $(0.33) YoY, but sales increased by 55.21% to $28.43M.
The significant decrease in EPS indicates higher losses, which is negative for the stock. However, the substantial increase in sales is a positive sign. Overall, the negative EPS is likely to have a stronger short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100